BlackRock Inc. acquired a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,498,248 shares of the company's stock, valued at approximately $1,323,047,000. BlackRock Inc. owned 8.95% of Medpace as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds have also recently made changes to their positions in MEDP. BOKF NA grew its stake in shares of Medpace by 0.8% in the third quarter. BOKF NA now owns 2,542 shares of the company's stock worth $1,307,000 after purchasing an additional 20 shares during the last quarter. Valeo Financial Advisors LLC raised its position in Medpace by 5.0% during the 4th quarter. Valeo Financial Advisors LLC now owns 444 shares of the company's stock valued at $249,000 after purchasing an additional 21 shares during the last quarter. UMB Bank n.a. lifted its holdings in Medpace by 5.6% in the 4th quarter. UMB Bank n.a. now owns 450 shares of the company's stock worth $253,000 after buying an additional 24 shares during the period. Schulhoff & Co. Inc. lifted its holdings in Medpace by 1.1% in the 4th quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company's stock worth $1,237,000 after buying an additional 25 shares during the period. Finally, Balefire LLC grew its position in shares of Medpace by 6.1% in the 1st quarter. Balefire LLC now owns 451 shares of the company's stock worth $217,000 after buying an additional 26 shares during the last quarter. Institutional investors own 77.98% of the company's stock.
Wall Street Analyst Weigh In
Several equities analysts have recently issued reports on MEDP shares. BMO Capital Markets boosted their target price on Medpace from $400.00 to $600.00 and gave the company a "market perform" rating in a research note on Friday, July 24th. Truist Financial lifted their price target on shares of Medpace from $462.00 to $609.00 and gave the company a "hold" rating in a report on Friday, July 24th. Leerink Partners set a $620.00 price objective on shares of Medpace in a research report on Thursday, July 23rd. Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a $535.00 price objective on shares of Medpace in a report on Thursday, July 23rd. Finally, TD Cowen raised their target price on shares of Medpace from $419.00 to $492.00 and gave the stock a "hold" rating in a research report on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company's stock. Based on data from MarketBeat, Medpace presently has an average rating of "Hold" and an average price target of $584.18.
Get Our Latest Analysis on Medpace
Medpace Price Performance
Shares of NASDAQ MEDP opened at $612.64 on Friday. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90. The firm has a 50-day moving average of $547.09 and a 200 day moving average of $491.80. The stock has a market cap of $17.10 billion, a P/E ratio of 35.91, a price-to-earnings-growth ratio of 2.71 and a beta of 1.15.
Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping analysts' consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business had revenue of $707.33 million for the quarter, compared to analysts' expectations of $689.51 million. During the same quarter in the prior year, the company earned $3.10 earnings per share. The business's revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Research analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, Director Cornelius P. Mccarthy III sold 1,140 shares of the company's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $605.37, for a total value of $690,121.80. Following the sale, the director owned 12,275 shares in the company, valued at $7,430,916.75. This represents a 8.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, General Counsel Stephen P. Ewald sold 16,349 shares of the firm's stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the transaction, the general counsel directly owned 20,343 shares of the company's stock, valued at approximately $9,154,350. This trade represents a 44.56% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 67,195 shares of company stock worth $37,989,998. 20.50% of the stock is currently owned by corporate insiders.
Medpace Company Profile
(
Free Report)
Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Medpace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.
While Medpace currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.
"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
